Independent
Tenure on this board
5.4 yrs
Also a director at
Actinium Pharmaceuticals Inc (ATNM)
Meeting calendar
TENX · Annual meeting · Tuesday, June 2, 2026
Tenax Therapeutics Inc
7 nominees · 2 ballot items.
Elect seven director nominees to one-year terms and ratify Cherry Bekaert LLP as the independent registered public accounting firm for fiscal year 2026.
Market cap
$420M
1Y TSR
+146.5%
Board grade
C-
Record date
Apr 8, 2026
Filing
DEF 14A
Meeting concluded · Jun 2, 2026
Follow how the vote landed and what changed on Tenax Therapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of Directors
ManagementBoard: FORElect the seven director nominees named in the proxy statement to serve one-year terms expiring in 2027 or until their successors are elected and qualified.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Cherry Bekaert LLP as Tenax Therapeutics' independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot7
Independent
Tenure on this board
5.4 yrs
Also a director at
Newamsterdam Pharma Co NV (NAMS)Bioage Labs Inc (BIOA)
Independent
Tenure on this board
5.4 yrs
Not independent
Tenure on this board
5.0 yrs
Independent
Tenure on this board
4.5 yrs
Independent
Tenure on this board
12.3 yrs
Also a director at
Dermata Therapeutics Inc (DRMA)
Not independent
Tenure on this board
5.4 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | PRICE T ROWE ASSOCIATES INC /MD/ | 11.1% | 2,951,116 | $47M |
| 2 | JANUS HENDERSON GROUP PLC | 6.8% | 1,815,474 | $29M |
| 3 | Venrock Adviser, LLC | 6.3% | 1,675,262 | $27M |
| 4 | PERCEPTIVE ADVISORS LLC | 5.5% | 1,447,782 | $23M |
| 5 | Ikarian Capital, LLC | 3.8% | 1,017,600 | $16M |
| 6 | Stonepine Capital Management, LLC | 3.7% | 975,200 | $16M |
| 7 | Logos Global Management LP | 2.4% | 625,000 | $10M |
| 8 | Velan Capital Investment Management LP | 2.2% | 583,333 | $9M |
| 9 | MORGAN STANLEY | 2.2% | 583,297 | $9M |
| 10 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.0% | 540,126 | $9M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Tenax Therapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Indaptus Therapeutics IncINDP
Annual meeting·Aug 10, 2026·$287M
Seer IncSEER
Annual meeting·Jul 28, 2026·$119M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$723M
Avanos Medical IncAVNS
Special meeting·Jul 22, 2026·$1.2B
Anaptysbio IncANAB
Annual meeting·Aug 11, 2026·$1.7B
Trulieve Cannabis CorpTRLV
Special meeting·Aug 5, 2026·$1.7B
Reference
Frequently asked questions
- When is the Tenax Therapeutics Inc 2026 annual meeting?
- Tenax Therapeutics Inc (TENX) holds its 2026 annual shareholder meeting on Tuesday, June 2, 2026.
- What is the record date for the Tenax Therapeutics Inc 2026 meeting?
- The record date for the Tenax Therapeutics Inc 2026 meeting is Wednesday, April 8, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Tenax Therapeutics Inc's 2026 meeting?
- The board is presenting 7 director nominees at the Tenax Therapeutics Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Tenax Therapeutics Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Tenax Therapeutics Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.